Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abeona Therapeutics (ABEO) Profit After Tax (2016 - 2025)

Abeona Therapeutics has reported Profit After Tax over the past 15 years, most recently at -$20.5 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$20.5 million for Q4 2025, down 120.17% from a year ago — trailing twelve months through Dec 2025 was $71.2 million (up 211.69% YoY), and the annual figure for FY2025 was $71.2 million, up 211.69%.
  • Profit After Tax for Q4 2025 was -$20.5 million at Abeona Therapeutics, down from -$5.2 million in the prior quarter.
  • Over the last five years, Profit After Tax for ABEO hit a ceiling of $108.8 million in Q2 2025 and a floor of -$46.7 million in Q4 2021.
  • Median Profit After Tax over the past 5 years was -$11.9 million (2023), compared with a mean of -$8.6 million.
  • Biggest five-year swings in Profit After Tax: tumbled 306.49% in 2023 and later surged 1369.52% in 2025.
  • Abeona Therapeutics' Profit After Tax stood at -$46.7 million in 2021, then surged by 84.75% to -$7.1 million in 2022, then crashed by 132.99% to -$16.6 million in 2023, then skyrocketed by 43.99% to -$9.3 million in 2024, then tumbled by 120.17% to -$20.5 million in 2025.
  • The last three reported values for Profit After Tax were -$20.5 million (Q4 2025), -$5.2 million (Q3 2025), and $108.8 million (Q2 2025) per Business Quant data.